Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA-Specific CTLs in Pediatric Lymphoma
NCT05134740Phase 1Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAA-CTL in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Baylor College of Medicine. Primary endpoint: Treatment-related adverse event Rate at 8 weeks. Planned start Apr 2024; status: withdrawn.
02
Drugs
TAA-CTL
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05134740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134740.